Relmada Net Income from 2010 to 2024
| RLMD Stock | USD 3.02 0.12 4.14% |
Net Loss | First Reported 2011-12-31 | Previous Quarter -17.8 M | Current Value -21.7 M | Quarterly Volatility 14.1 M |
Check Relmada Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relmada Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 108.9 M, Selling General Administrative of 51.3 M or Selling And Marketing Expenses of 14.9 M, as well as many indicators such as Price To Sales Ratio of 8.8 K, Dividend Yield of 0.0 or PTB Ratio of 1.39. Relmada financial statements analysis is a perfect complement when working with Relmada Therapeutics Valuation or Volatility modules.
Relmada | Net Income |
Latest Relmada Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Relmada Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Relmada Therapeutics financial statement analysis. It represents the amount of money remaining after all of Relmada Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Relmada Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relmada Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (98.79 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Relmada Net Income Regression Statistics
| Arithmetic Mean | (40,808,295) | |
| Coefficient Of Variation | (129.16) | |
| Mean Deviation | 44,113,928 | |
| Median | (17,318,060) | |
| Standard Deviation | 52,707,948 | |
| Sample Variance | 2778.1T | |
| Range | 157M | |
| R-Value | (0.80) | |
| Mean Square Error | 1058.9T | |
| R-Squared | 0.65 | |
| Significance | 0.0003 | |
| Slope | (9,473,280) | |
| Total Sum of Squares | 38893.8T |
Relmada Net Income History
Other Fundumenentals of Relmada Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
About Relmada Therapeutics Financial Statements
Relmada Therapeutics stakeholders use historical fundamental indicators, such as Relmada Therapeutics' Net Income, to determine how well the company is positioned to perform in the future. Although Relmada Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Relmada Therapeutics' assets and liabilities are reflected in the revenues and expenses on Relmada Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Relmada Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out the analysis of Relmada Therapeutics Correlation against competitors. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.